News

Article

Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma

Author(s):

Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma who are ineligible to undergo a transplant.

This article was originally published by CancerNetwork.

Treatment with axicabtagene ciloleucel (axi-cel; Yescarta) produced high anti-tumor activity and a manageable safety profile among patients with high-risk relapsed/refractory large B-cell lymphoma (LBCL) who are unsuitable to undergo autologous stem cell transplantation (ASCT), according to findings from the phase 2 ALYCANTE trial (NCT04531046) published in Nature Medicine.1

CAR T cell | Image credit: Maverick - stock.adobe.com

CAR T cell | Image credit: Maverick - stock.adobe.com

A single infusion of axi-cel yielded a 3-month complete metabolic response (CMR) rate of 71.0% (95% CI, 58.1%-81.8%) among 62 patients in a modified full analysis set based on Lugano response criteria. Additionally, the investigator-assessed CMR at this time was 66.7% (95% CI, 54.3%-77.6%). Additionally, 5 of 10 patients had a partial metabolic response at 1 month and eventually experienced a CMR at 3 months.

The investigator-assessed overall response rate (ORR) was 75.8% (95% CI, 63.3%-85.8%), and 59.7% (95% CI, 46.5%-72.0%) of patients maintained a CMR at 6 months. Investigators also reported a median event-free survival (EFS) of 12.3 months (95% CI, 7.2-not reached [NR]) from leukapheresis after a median follow-up of 12.0 months in the full analysis set (n = 69). EFS was estimated to be 66.7% (95% CI, 54.2%-76.4%) at 6 months and 51.2% (95% CI, 38.2%-62.8%) at 12 months.

Patients treated with axi-cel experienced a median progression-free survival (PFS) of 11.8 months (95% CI, 8.4-NR). Additionally, the estimated PFS rates were 67.7% (95% CI, 54.5%-77.8%) at 6 months and 48.8% (95% CI, 34.0%-62.0%) at 12 months. Investigators highlighted that the median overall survival (OS) was not reached, and that the 6-month and 12-month OS rates, respectively, were 91.9% (95% CI, 81.6%-96.5%) and 78.3% (95% CI, 64.7%-87.1%). The median duration of response (DOR) was not reached in the study.

“Transplant ineligible patients with aggressive relapsed or refractory B-cell lymphomas face poor prognosis,” lead study author Roch Houot, professor and head of the Haematology Department at University Hospital of Rennes, France, said in a press release on these findings.2 “ALYCANTE is the first study to assess [axi-cel] as second-line therapy for transplant ineligible R/R LBCL and the results showed high response rates and durable remission in this hard-to-treat population.”

Investigators of the open-label phase 2 ALYCANTE study evaluated second-line axi-cel as a treatment for patients with relapsed/refractory LBCL who were not suitable to undergo ASCT. Patients received lymphodepleting conditioning chemotherapy for 3 days followed by a single infusion of axi-cel at a target dose of 2x106 CAR T cells/kg of body weight.

The study’s primary end point was 3-month CMR rate per Lugano response criteria. Secondary end points included ORR, DOR, EFS, PFS, and OS.


Patients 18 years and older with histologically confirmed aggressive B-cell non-Hodgkin lymphoma according to 2016 World Health Organization criteria were able to enroll on the study. Additional eligibility criteria included having an ECOG performance status of 0 to 2 and adequate vascular access for leukapheresis.

The median patient age was 70.0 years (range, 49.0-81.0), and 75.8% of patients were male. Additionally, most patients had an ECOG performance status of 0 or 1 (98.4%), Ann Arbor stage III or IV disease (74.2%), and diffuse LBCL not otherwise specified (83.9%). All patients received chemoimmunotherapy in the first-line setting (100%), with the most common regimen being rituximab (Rituxan) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (58.1%).

The 3-month CMR rate was 72.7% in patients 70 years and older (n = 33) compared with 69.0% in those younger than 70 (n = 29). Investigators reported that survival outcomes, DOR, and toxicity were similar between these age groups. In those with a hematopoietic cell transplantation-specific comorbidity index (HCT-CI) of 3 or higher (n = 20), the 3-month CMR rate was 80.0%; these patients experienced survival outcomes and toxicity that were comparable with those who had an HCT-CI of lower than 3 (n = 42).

Investigators reported grade 3 or higher adverse effects (AEs) in 95.2% of the study population, which mostly included neutropenia (66.1%), anemia (38.7%), and thrombocytopenia (38.7%). Any-grade infections occurred in 53.2%, which included COVID-19 in 24.2%.

Overall, 93.5% of patients had any-grade cytokine release syndrome (CRS), with 8.1% of these toxicities being grade 3 or higher. Investigators reported a median time to CRS onset of 1.5 days (interquartile range [IQR], 1.0-3.0) and a median CRS duration of 5.0 days (IQR, 4.0-9.0). Additionally, 51.6% of patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS), and 14.5% of patients had grade 3 or higher toxicity. The median time to ICANS onset was 6.0 days (IQR, 5.0-8.0), and the median duration was 5.0 days (IQR, 3.0-8.0).

References

1. Houot R, Bachy E, Cartron G, et al. Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. Nat Med. Published online September 14, 2023. doi:10.1038/s41591-023-02572-5

2. Kite’s CAR T-cell therapy Yescarta® demonstrates high response rate and durable remission in ALYCANTE study as initial treatment for transplant ineligible patients with relapsed/refractory large B-cell lymphoma. News release. Kite, a Gilead Company. September 18, 2023. Accessed September 18, 2023. https://shorturl.at/amAG0

Related Videos
Parth Rali, MD
1 KOL is featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
Screenshot during an interview with Aaron Adkisson, PharmD
Benjamin Scirica, MD, MPH, associate professor of medicine at Harvard Medical School and director of quality initiatives at Brigham and Women’s Hospital’s Cardiovascular Division
Laurence Sperling, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo